Literature DB >> 3132465

Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain.

T Kondo1, D FitzGerald, V K Chaudhary, S Adhya, I Pastan.   

Abstract

Pseudomonas exotoxin (PE) contains three domains whose functions are cell recognition, membrane translocation, and ADP ribosylation of elongation factor 2. PE40 is a form of PE which is missing the cell recognition domain. To study the properties of PE40, it was expressed in Escherichia coli using a vector which contains a T7 phage promoter, an OmpA signal sequence, and that portion of the PE gene encoding PE40. Upon induction with isopropyl-1-thio-beta-D-galactopyranoside, large amounts of PE40 were secreted, and highly purified PE40 was prepared from the culture medium. PE40 was chemically coupled to different monoclonal antibodies, and protein synthesis inhibition activities of these immunotoxins was assessed on various cell lines. These activities were compared with the activities of the corresponding immunotoxins made with native PE. These data indicate that PE40 may be useful in the construction of certain immunotoxins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132465

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  36 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.

Authors:  V K Chaudhary; J K Batra; M G Gallo; M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.

Authors:  John F Langenheim; Wen Y Chen
Journal:  Breast Cancer Res Treat       Date:  2005-04       Impact factor: 4.872

4.  Production of unique immunotoxin cancer therapeutics in algal chloroplasts.

Authors:  Miller Tran; Christina Van; Daniel J Barrera; Pär L Pettersson; Carlos D Peinado; Jack Bui; Stephen P Mayfield
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

5.  Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.

Authors:  Christopher M Pirie; Benjamin J Hackel; Michael G Rosenblum; K Dane Wittrup
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

6.  Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody.

Authors:  L Blanco; E M Choi; K Connolly; M R Thompson; P F Bonventre
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

7.  Deimmunizing substitutions in Pseudomonas exotoxin domain III perturb antigen processing without eliminating T-cell epitopes.

Authors:  Daniel L Moss; Hee-Won Park; Ramgopal R Mettu; Samuel J Landry
Journal:  J Biol Chem       Date:  2019-01-25       Impact factor: 5.157

Review 8.  Immunotoxin therapy for CNS tumor.

Authors:  Edward Rustamzadeh; Walter C Low; Daniel A Vallera; Walter A Hall
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

9.  Cytotoxicity against human peripheral blood mononuclear cells and T cell lines mediated by anti-T cell immunotoxins in the absence of added potentiator.

Authors:  D M Fishwild; M O Staskawicz; H M Wu; S F Carroli
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

10.  CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses.

Authors:  E A Berger; K A Clouse; V K Chaudhary; S Chakrabarti; D J FitzGerald; I Pastan; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.